Cancer-Focused Medivir Licenses AMR Centre Promising Superbug Assets

 
• By Sten Stovall

Medivir has licensed to the UK's AMR Centre exclusive worldwide rights to its superbug MBLI program in return for a share of eventual sales from generated therapies.

Klebsiella
AMRC Will Develop Compounds From Medivir’s Anti-Superbug MBLI Program • Source: Shutterstock

More from Strategy

More from Business